Showing 20 of 183 recruiting trials for “hepatocellular-carcinoma”
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
👨⚕️ Fangjian Zhou, Professor, Director of Dept. of Urology, Sun Yat-sen University Cancer Center📍 8 sites📅 Started Apr 2023View details ↗
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
👨⚕️ Anthony B El-Khoueiry, MD, University of Southern California📍 2 sites📅 Started Mar 2023View details ↗
The Application of Serum DNA Methylation for Patients With HCC
👨⚕️ Po-Yueh Chen, M.D, Ditmanson Medical Foundation Chiayi Christian Hospital📍 1 site📅 Started Mar 2023View details ↗
RecruitingNCT05184790 ↗
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
RecruitingNCT06806579 ↗
Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
👨⚕️ Francesco Tovoli, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 24 sites📅 Started Dec 2022View details ↗
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
👨⚕️ Brian I Rini, MD, Vanderbilt University/Ingram Cancer Center📍 6 sites📅 Started Dec 2022View details ↗
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
👨⚕️ Cai Jian qiang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 5 sites📅 Started Nov 2022View details ↗
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Nov 2022View details ↗
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
RecruitingNCT06088134 ↗
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
👨⚕️ Wenxiong Xu, Doctor, Third Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Aug 2022View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →